EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators EZH2 and HDAC

Amy E Schade iD, Ryan Kuzmickas iD, Carrie L Rodriguez, Kaia Mattioli, Miriam Enos, Alycia Gardner, Karen Cichowski

PLOS Biology · 2023

DOI: 10.1371/journal.pbio.3002038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Biology, 2023. Verfasst von Amy E Schade und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Genetics, Brigham and Women's Hospital, Boston, Massachusetts, United States of America. Hauptthemen laut MEDLINE: Histones, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Cancer Research UK, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While screening and early detection have reduced mortality from prostate cancer, castration-resistant disease (CRPC) is still incurable. Here, we report that combined EZH2/HDAC inhibitors potently kill CRPCs and cause dramatic tumor regression in aggressive human and mouse CRPC models. Notably, EZH2 and HDAC both transmit transcriptional repressive signals: regulating histone H3 methylation and histone deacetylation, respectively. Accordingly, we show that suppression of both EZH2 and HDAC are required to derepress/induce a subset of EZH2 targets, by promoting the sequential demethylation and acetylation of histone H3. Moreover, we find that the induction of one of these targets, ATF3 , which is a broad stress response gene, is critical for the therapeutic response. Importantly, in human tumors, low ATF3 levels are associated with decreased survival. Moreover, EZH2 - and ATF3- mediated transcriptional programs inversely correlate and are most highly/lowly expressed in advanced disease. Together, these studies identify a promising therapeutic strategy for CRPC and suggest that these two major epigenetic regulators buffer prostate cancers from a lethal response to cellular stresses, thereby conferring a tractable therapeutic vulnerability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HistonesProstatic Neoplasms, Castration-ResistantAnimalsHumansMaleMiceCell Line, TumorEnhancer of Zeste Homolog 2 ProteinEpigenesis, GeneticGene Expression Regulation, NeoplasticHistone Deacetylases

Substanzen

Enhancer of Zeste Homolog 2 ProteinEZH2 protein, humanHistonesEzh2 protein, mouseHistone Deacetylases

Autor:innen und Institutionen

  • Department of Medicine, Division of Genetics, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
  • Harvard Medical School, Boston, Massachusetts, United States of America.
  • Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts, United States of America.

ORCID-Profile: Amy E Schade, Ryan Kuzmickas

Förderung

  • NCI NIH HHS
  • Cancer Research UK
  • National Cancer Institute
  • Mark Foundation For Cancer Research
  • American Cancer Society

Zitieren

APA

Schade, A. E., Kuzmickas, R., Rodriguez, C. L., Mattioli, K., Enos, M., Gardner, A., & Cichowski, K. (2023). Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators EZH2 and HDAC. PLOS Biology. https://doi.org/10.1371/journal.pbio.3002038

Vancouver

Schade AE, Kuzmickas R, Rodriguez CL, Mattioli K, Enos M, Gardner A, et al. Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators EZH2 and HDAC. PLOS Biology. 2023. doi:10.1371/journal.pbio.3002038

BibTeX
@article{Schade2023,
  author = {Schade, Amy E and Kuzmickas, Ryan and Rodriguez, Carrie L and Mattioli, Kaia and Enos, Miriam and Gardner, Alycia and Cichowski, Karen},
  title = {Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators EZH2 and HDAC},
  journal = {PLOS Biology},
  year = {2023},
  doi = {10.1371/journal.pbio.3002038}
}
Kostenlos starten →